Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy. Despite initial responsiveness, many patients experience rapid relapse driven by cancer stem-like cells that survive chemotherapy and seed metastasis.
This article was originally published on MedicalXpress.com

